Galectin Therapeutics (GALT) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Galectin Therapeutics (GALT) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 17.1% versus a loss of 63.5%. Over five years, GALT leads with a +16.9% price change compared with -53.8% for SPRY. ARS Pharmaceuticals is the larger company by market cap ($420.7 million vs $397.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | SPRY |
|---|---|---|
| Share price | $3.94 | $4.23 |
| Market cap | $397.35M | $420.66M |
| 1-day change | +8.24% | -7.24% |
| YTD return | -5.29% | -63.69% |
| 1-year return | -17.05% | -63.47% |
| 5-year return | +16.91% | -53.75% |
| EPS (TTM) | $-0.47 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.13 | $13.15 |
| 52-week low | $2.03 | $3.99 |
| Distance from 52-week high | -44.74% | -67.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +179.19% | +431.91% |
| Average volume | 377.40K | 1.86M |
| Shares outstanding | 100.85M | 99.45M |
| Employees | 9 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GALT has outperformed SPRY by 46.4 percentage points over the past year.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
GALT vs SPRY FAQ
Which is bigger, Galectin Therapeutics or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $420.66M compared with $397.35M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, GALT or SPRY?
GALT returned -17.05% over the past 12 months, compared with -63.47% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.